Prednisolone in Severe Alcoholic Hepatitis
- 1 Clinical Question
- 2 Bottom Line
- 3 Major Points
- 4 Guidelines
- 5 Design
- 6 Population
- 7 Interventions
- 8 Outcomes
- 9 Criticisms
- 10 Funding
- 11 Further Reading
In patients with severe alcoholic hepatitis, does prednisolone improve survival?
In patients with severe alcoholic hepatitis, prednisolone improves 2-month survival.
Alcoholic hepatitis carries up to a 65% mortality rate, and because therapy generally has consisted mainly of supportive measures, many investigators have sought out disease-modifying interventions. In a sea of studies yielding conflicting results, the present 1992 study was one of the first to suggest a survival benefit of glucocorticoids among patients with severe alcoholic hepatitis.
This trial randomized 61 patients with severe, biopsy-proven alcoholic hepatitis to prednisolone or placebo. Severe disease was determined by the presence of hepatic encephalopathy or Maddrey's discriminant function (DF) >32. At 2 months, survival was significantly better in patients receiving prednisolone (88% vs. 45%) with a NNT of 3. This survival benefit was also seen at 6 months. In contrast to other trials, the prednisolone group experienced fewer GI bleeds and infections, which one would have expected to be more common in the glucocorticoid group.
Since the publication of this trial, two positive meta-analyses have again underscored that steroids are most beneficial among those with severe alcoholic hepatitis, manifested by encephalopathy or DF >32. A 2008 Cochrane Review  suggests that there is insufficient data to support or advise against the routine use of steroids in alcoholic hepatitis. The 2009 AASLD/ACG guidelines recommend consideration of prednisolone for patients with severe alcoholic hepatitis (based upon the presence of hepatic encephalopathy or DF ≥32), and supportive treatment alone for those with mild to moderate disease.
The subsequent Pentoxifylline in Severe Alcoholic Hepatitis (2000) suggested that pentoxifylline may also improve survival in severe alcoholic hepatitis. The 2015 STOPAH trial randomized patients to pentoxifylline, prednisolone, or placebo. There was no mortality benefit with pentoxifylline, but prednisolone was associated with a non-significant trend towards mortality reduction at 28 days (OR 0.72; 95% CI 0.52-1.01; P=0.06).
AASLD/ACG Alcoholic Liver Disease (2010, adapted)
- For patients with alcoholic hepatitis:
- Alcohol abstinence counseling (class I, level B)
- Assessment for nutritional, vitamin, and mineral deficiencies with aggressive repletion in those with severe disease (class I, level B)
- If mild-moderate (Maddrey score <32), no hepatic encephalopathy, and improvement in bilirubin or decline in Maddrey score, unlikely to benefit from medical interventions except abstinence and nutritional support (class III, level A)
- If severe (Maddrey score ≥32) regardless of hepatic encephalopathy, if no conraindications to corticosteroids, consider four weeks of prednisone at 40 mg/day for 28 days then discontinuation or tapering dose over two weeks (class I, level A)
- If severe (Maddrey score ≥32), consider pentoxifylline 400 mg PO TID for 28 days, especially if corticosteroid contraindications (class I, level B)
- Double-blind, parallel group, randomized, placebo-controlled trial
- Prednisolone (n=32)
- Placebo (n=29)
- Setting: two centers in France
- Enrollment: 1987-1990
- Follow-up: 6 months
- Analysis: not specified
- Primary end point: 60-day survival
- Chronic alcoholism and clinical features of alcoholic hepatitis
- Biopsy-proven alcoholic hepatitis, characterized by hyaline necrosis and infiltration of polymorphonuclear leukocytes
- Hepatic encephalopathy and/or Maddrey's discriminant function >32
- Gastrointestinal bleeding
- Bacterial infection
- Liver biopsy negative for alcoholic hepatitis
- Gastric or duodenal ulcer
- Presence of HBsAg
- Presence of HIV antibodies
- Anticoagulation therapy
- Age: 48 years
- Female: 69%
- Ascites: 80%
- Encephalopathy: 31%
- Esophageal varices: 51%
- Hepatic venous pressure gradient: 19.5 mmHg
- Bilirubin: 14.4 mg/dL
- PT: 38% normal
- AST: 3.5 x ULN
- Albumin: 402 umol/L
- Hgb: 6.4 mmol/L
- Discriminant function: 55
- HBV and HIV serologies, gastroscopy, liver biopsy
- Discriminant function: 4.6 (PT - control time in seconds) + serum bilirubin (mmol/L)/17
- Randomized to either prednisolone 40 mg or placebo by mouth every morning for 28 days.
- Routine treatment regimen included:
- 3,000 cal diet with 1g protein/kg TBW
- Lactulose for hepatic encephalopathy
- Sodium restriction or spironolactone for ascites
- Fluid restriction for hyponatremia
- B-complex vitamins, folate, and antacids supplementation
Comparisons are prednisolone vs. placebo.
- 60-day survival
- 88% vs. 45% (P=0.001; NNT=3)
- 30-day survival
- 88% vs. 62%
- 6-month survival
- 84% vs. 45% (P=0.002; NNT=3)
- Survival advantage for prednisolone persisted after stratification according to center and presence of encephalopathy, and after adjustment for prognostic factors.
- Worsening of psychiatric disorders and glucose intolerance was noted in one member of the prednisolone group.
- Infection and GI bleeding were more common in the placebo group.
- Delay from admission to randomization in order to get liver biopsy
- Patients in the placebo group may have more severe disease with higher baseline creatinine, bilirubin and DF. 
- Nearly 70% women renders the results difficult to generalize. In US, 60-70% patients with alcoholic hepatitis are male. In addition, some studies have demonstrated that females may have more favorable responses to glucocorticoids. 
- 2008 Cochrane review on glucocorticoids in alcoholic hepatitis
- AASLD Practice Guidelines on Alcoholic Liver Disease
- Thursz MR, et al. "Prednisolone or pentoxifylline for alcoholic hepatitis." The New England Journal of Medicine. 2015;371(17):1619-1628.
- O'Shea RS, et al. "Alcoholic Liver Disease." Hepatology. 2010;51(1):307-328.
- NEJM Letters to the Editor